What is the address of CARDIOPERF?

The registered office of CARDIOPERF is located at Kleetboslaan 20, 1650 Beersel.

Is CARDIOPERF still active?

Yes. According to the CBE (16 September 2026) CARDIOPERF is active, legal situation “Normale toestand”, started on 8 March 2013.

Is CARDIOPERF registered on Peppol?

Yes, CARDIOPERF is registered on the Peppol network with ID 0208:0521874648.

What is the enterprise number of CARDIOPERF?

The enterprise number of CARDIOPERF is BE0521874648.

When was CARDIOPERF founded?

CARDIOPERF was founded on 8 March 2013.

Who are the directors of CARDIOPERF?

According to the 2024 annual accounts, the directors of CARDIOPERF are: Xavier Bechtold.

Is CARDIOPERF a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 8 March 2013; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did CARDIOPERF make in 2024?

CARDIOPERF posted a profit after taxes of € 15,714 in financial year 2024.

What is the revenue of CARDIOPERF?

As a small company, CARDIOPERF is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 20,256.

CARDIOPERF (Private Limited) - Beersel - BE0521874648

Dossier CARDIOPERF, printed on 16 September 2026 from databakkes.be/en/0521874648/cardioperf. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2024

CARDIOPERF from Beersel, company number BE0521874648, closed financial year 2024 with a result of € 15,714 after tax. For that financial year CARDIOPERF recorded a gross margin of € 20,256 and equity of € 142,727. Compared with financial year 2023, the result moved from € 22,885 to € 15,714. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 1, 2025.

What it is worth Growing

€ 142,727

▲ 12% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 15,714

▼ 31% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 10,926

▲ 130% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 136,527.

People and assets in 2024

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2024

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 726

▲ 20% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 20,061

▲ 5% vs 2023

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 22,249 Gross margin 2021: € 22,249 First fiscal year in the series	€ 21,829 Gross margin 2022: € 21,829 ▼ 2% vs 2021 (€ 22,249) Unfavourable step	€ 31,574 Gross margin 2023: € 31,574 ▲ 45% vs 2022 (€ 21,829) Favourable step	€ 20,256 Gross margin 2024: € 20,256 ▼ 36% vs 2023 (€ 31,574) Unfavourable step	▼ 36%
Profit after taxes	€ 12,562 Profit after taxes 2021: € 12,562 First fiscal year in the series	€ 10,739 Profit after taxes 2022: € 10,739 ▼ 15% vs 2021 (€ 12,562) Unfavourable step	€ 22,885 Profit after taxes 2023: € 22,885 ▲ 113% vs 2022 (€ 10,739) Favourable step	€ 15,714 Profit after taxes 2024: € 15,714 ▼ 31% vs 2023 (€ 22,885) Unfavourable step	▼ 31%
Equity	€ 93,390 Equity 2021: € 93,390 First fiscal year in the series	€ 104,129 Equity 2022: € 104,129 ▲ 11% vs 2021 (€ 93,390) Favourable step	€ 127,014 Equity 2023: € 127,014 ▲ 22% vs 2022 (€ 104,129) Favourable step	€ 142,727 Equity 2024: € 142,727 ▲ 12% vs 2023 (€ 127,014) Favourable step	▲ 12%
Total debts	€ 18,189 Total debts 2021: € 18,189 First fiscal year in the series	€ 15,069 Total debts 2022: € 15,069 ▼ 17% vs 2021 (€ 18,189) Favourable step	€ 20,152 Total debts 2023: € 20,152 ▲ 34% vs 2022 (€ 15,069) Unfavourable step	€ 20,787 Total debts 2024: € 20,787 ▲ 3% vs 2023 (€ 20,152) Unfavourable step	▲ 3%
Cash	€ 3,285 Cash 2021: € 3,285 First fiscal year in the series	€ 6,472 Cash 2022: € 6,472 ▲ 97% vs 2021 (€ 3,285) Favourable step	€ 4,749 Cash 2023: € 4,749 ▼ 27% vs 2022 (€ 6,472) Unfavourable step	€ 10,926 Cash 2024: € 10,926 ▲ 130% vs 2023 (€ 4,749) Favourable step	▲ 130%
Retained profit	€ 87,190 Retained profit 2021: € 87,190 First fiscal year in the series	€ 97,929 Retained profit 2022: € 97,929 ▲ 12% vs 2021 (€ 87,190) Favourable step	€ 120,814 Retained profit 2023: € 120,814 ▲ 23% vs 2022 (€ 97,929) Favourable step	€ 136,527 Retained profit 2024: € 136,527 ▲ 13% vs 2023 (€ 120,814) Favourable step	▲ 13%
Balance sheet total	€ 111,578 Balance sheet total 2021: € 111,578 First fiscal year in the series	€ 119,197 Balance sheet total 2022: € 119,197 ▲ 7% vs 2021 (€ 111,578) Unchanged	€ 147,165 Balance sheet total 2023: € 147,165 ▲ 23% vs 2022 (€ 119,197) Unchanged	€ 163,514 Balance sheet total 2024: € 163,514 ▲ 11% vs 2023 (€ 147,165) Unchanged	▲ 11%

Key figures of CARDIOPERF, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to CARDIOPERF?

What happened at CARDIOPERF in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 1, 2025 New annual accounts for financial year 2024: profit of € 15,714 (▼ 31% vs 2023). filed late Source: NBB ↗
Mar 8, 2013 New establishment in Beersel. KBO
Mar 8, 2013 Start of the company according to the CBE. KBO
2013 Xavier Bechtold became a director. NBB

In short

From € 12,562 profit in 2021 to € 15,714 profit in 2024.

Paid € 34,634 in corporate taxes since 2021.

Best year ever: 2023, with € 22,885 profit.

Original PDFs at the National Bank ↗

A new publication or filing at CARDIOPERF? We notify you, reason included.

Follow CARDIOPERF

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit